外科理论与实践 ›› 2024, Vol. 29 ›› Issue (02): 143-147.doi: 10.16139/j.1007-9610.2024.02.09
收稿日期:
2024-01-23
出版日期:
2024-03-25
发布日期:
2024-07-01
通讯作者:
杨军,E-mail:zergbay@163.com
SONG Qingjie, TANG Juanjuan, ZHAO Jianquan, SONG hui, YANG Jun()
Received:
2024-01-23
Online:
2024-03-25
Published:
2024-07-01
摘要:
目的:分析高脂血症及降脂治疗对乙肝相关肝细胞癌病人术后预后的影响。方法:回顾性收集2012年1月至2021年1月于本院普外科手术的乙肝相关肝细胞癌病人,分析其血脂水平和相关降脂治疗对乙肝相关肝细胞癌病人术后预后的影响。结果:166例乙肝相关肝细胞癌病人中高脂血症63例,其中33例使用他汀类药物。高脂血症组术后中位无病生存时间明显低于正常血脂组(24.8个月对比38.5个月,P<0.05),高脂血症组中位总生存期也明显低于正常血脂组(30.1个月对比44.5个月,P<0.05)。高脂血症病人使用他汀类药物后(中位无病生存时间为23.4个月,中位总体生存时间为29.7个月),与未使用的高脂血症病人(中位无病生存时间为26.3个月,中位总体生存时间为30.3个月)的预后差异无统计学意义。结论:乙肝相关肝细胞癌病人高脂血症是其术后无病生存和总生存的危险因素,但在高脂血症病人中单纯使用他汀类药物降脂并不能减少其复发风险,延长生存时间。
中图分类号:
宋庆杰, 汤娟娟, 赵健全, 宋辉, 杨军. 高脂血症对乙肝相关肝细胞癌病人预后的影响[J]. 外科理论与实践, 2024, 29(02): 143-147.
SONG Qingjie, TANG Juanjuan, ZHAO Jianquan, SONG hui, YANG Jun. Effect of hyperlipidemia on prognosis of the patients with hepatitis B related hepatocellular carcinoma[J]. Journal of Surgery Concepts & Practice, 2024, 29(02): 143-147.
表1
高脂血症与临床病理特征的关系[n(%)]
Clinical pathological characteristics | Hyperlipidemia | ||||
---|---|---|---|---|---|
Total | No | Yes | χ2 value | P value | |
Age (years) | 0.094 | 0.759 | |||
≤50 | 22 | 13(59.1) | 9(40.9) | ||
>50 | 144 | 90(62.5) | 54(37.5) | ||
Gender | 0.889 | 0.346 | |||
Man | 114 | 68(59.6) | 46(40.4) | ||
Woman | 52 | 35(67.3) | 17(32.4) | ||
Tumor diameter(cm) | 0.019 | 0.889 | |||
≤5 | 99 | 61(61.6) | 38(38.4) | ||
>5 | 67 | 42(62.7) | 25(37.3) | ||
Microvascular cancer thrombus | 2.371 | 0.124 | |||
Yes | 59 | 32(54.2) | 27(45.8) | ||
No | 107 | 71(66.4) | 36(33.6) | ||
TNM stage | 0.989 | 0.320 | |||
Ⅰ | 69 | 43(62.3) | 26(37.7) | ||
Ⅱ+Ⅲ | 97 | 60(61.9) | 37(38.1) |
表2
高脂血症与正常血脂HCC病人OS期和OS率[n(%)/$\bar{x}$±s]
Item | Hyperlipidemia group (n=63) | Normal blood lipid group (n=103) | χ2/t value | P value |
---|---|---|---|---|
Accumulated 1-year survival rate | 61(96.8) | 103(100) | ||
Accumulated 3-year survival rate | 47(74.6) | 83(80.6) | 750 | 0.000 |
Accumulated 5-year survival rate | 28(44.4) | 53(51.5) | ||
OS (months) | 30.1±11.9 | 44.5±15.6 | -6.708 | 0.000 |
表3
高脂血症与正常血脂HCC病人DFS期和复发率[n(%)/$\bar{x}$±s]
Item | Hyperlipidemia group (n=63) | Normal blood lipid group (n=103) | χ2/t value | P value |
---|---|---|---|---|
Accumulated 1-year recurrence rate | 16(25.4) | 11(10.7) | ||
Accumulated 3-year recurrence rate | 35(55.6) | 53(51.5) | 452 | 0.000 |
Accumulated 5-year recurrence rate | 45(71.4) | 66(64.1) | ||
DFS (months) | 24.8±10.9 | 38.5±18.5 | -5.335 | 0.000 |
[1] | SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. |
[2] |
DE MARTEL C, MAUCORT-BOULCH D, PLUMMER M, et al. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma[J]. Hepatology, 2015, 62(4):1190-1200.
doi: 10.1002/hep.27969 pmid: 26146815 |
[3] | LIU J, ZHANG S K, WANG Q M, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based,cross-sectional study[J]. Lancet Infect Dis, 2016, 16(1):80-86. |
[4] | 黄纪伟, 邱国腾, 曾勇. 肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(2):113-118. |
HUANG J W, QIU G T, ZENG Y. Advances in the surgical treatment of hepatocellular carcinoma[J]. J Surg Concepts Pract, 2022, 27(2):113-118. | |
[5] |
PHAN J, NG V, SHEINBAUM A, et al. Hyperlipidemia and nonalcoholic steatohepatitis predispose to hepatocellular carcinoma development without cirrhosis[J]. J Clin Gastroenterol, 2019, 53(4):309-313.
doi: 10.1097/MCG.0000000000001062 pmid: 29912756 |
[6] | PAUL B, LEWINSKA M, ANDERSEN J B. Lipid alterations in chronic liver disease and liver cancer[J]. JHEP Rep, 2022, 4(6):100479. |
[7] | 由金玲, 徐晓慧, 林琳, 等. 基于GBD数据分析1990年和2019年中国人群癌谱差异[J]. 中国肿瘤, 2024, 33(1):36-43. |
YOU J L, XU X H, LIN L, et al. Analysis of cancer spectrum in China based on GBD data in 1990 and 2019[J]. China Cancer, 2024, 33(1):36-43. | |
[8] | GONG F, YANG N L, WANG X W, et al. Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics[J]. Nano Today, 2020,32:100851 |
[9] | ZHENG J, GAO P. Toward normalization of the tumor microenvironment for cancer therapy[J]. Integr Cancer Ther, 2019,18:1534735419862352. |
[10] |
PORPORATO P E, PAYEN V L, DE SAEDELEER C J, et al. Lactate stimulates angiogenesis and accelerates the healing of superficial and ischemic wounds in mice[J]. Angiogenesis, 2012, 15(4):581-592.
doi: 10.1007/s10456-012-9282-0 pmid: 22660894 |
[11] | SUNDELIN J P, LIDBERG U, NIK A M, et al. Hypoxia-induced regulation of the very low density lipoprotein receptor[J]. Biochem Biophys Res Commun, 2013, 437(2):274-279. |
[12] |
VERNIERI C, CASOLA S, FOIANI M, et al. Targeting cancer metabolism: dietary and pharmacologic interventions[J]. Cancer Discov, 2016, 6(12):1315-1333.
pmid: 27872127 |
[13] |
STOPSACK K H, GERKE T A, SINNOTT J A, et al. Cholesterol metabolism and prostate cancer lethality[J]. Cancer Res, 2016, 76(16):4785-4790.
doi: 10.1158/0008-5472.CAN-16-0903 pmid: 27325648 |
[14] |
LYU J, YANG E J, HEAD S A, et al. Astemizole inhibits mTOR signaling and angiogenesis by blocking cholesterol trafficking[J]. Int J Biol Sci, 2018, 14(10):1175-1185.
doi: 10.7150/ijbs.26011 pmid: 30123067 |
[15] | LYU J, YANG E J, HEAD S A, et al. Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth[J]. Cancer Lett, 2017,409:91-103. |
[16] | WOOD F A, HOWARD J P, FINEGOLD J A, et al. N-of-1 trial of a statin, placebo,or no treatment to assess side effects[J]. N Engl J Med, 2020, 383(22):2182-2184. |
[17] | YANG F, KOU J, LIU Z, et al. MYC enhances cholesterol biosynthesis and supports cell proliferation through SQLE[J]. Front Cell Dev Biol, 2021,9:655889. |
[18] |
LEBEAU P F, BYUN J H, PLATKO K, et al. Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance[J]. Nat Commun, 2022, 13(1):770.
doi: 10.1038/s41467-022-28240-9 pmid: 35140212 |
[19] | CHEN J, DING C, CHEN Y, et al. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway[J]. Cancer Lett, 2021, 502:154-165. |
[20] | ZHANG F, GAO J, LIU X, et al. LATS‐regulated nuclear‐cytoplasmic translocation of SREBP2 inhibits hepatocellular carcinoma cell migration and invasion via epithelial-mesenchymal transition[J]. Mol Carcinog, 2023, 62(7):963-974. |
[1] | 林起柱, 刘红枝, 黄霆峰, 范瑞林, 周伟平, 郑树国, 楼健颖, 曾永毅. 基于肝内胆管癌预后模型筛选辅助化疗受益人群[J]. 外科理论与实践, 2024, 29(02): 170-178. |
[2] | 邵卫清, 陆录, 钦伦秀. 系统疗法改变肝癌外科的格局:机遇与挑战[J]. 外科理论与实践, 2024, 29(02): 93-98. |
[3] | 施纯朝, 王葵. 2023年第2版NCCN肝细胞癌临床实践指南解读[J]. 外科理论与实践, 2024, 29(02): 99-105. |
[4] | 赵磊, 钟敬涛, 孙惠川. 肝细胞癌的转化治疗中几个重要却尚无答案的问题[J]. 外科理论与实践, 2024, 29(02): 106-113. |
[5] | 莫建涛, 曹瑞奇, 任加强, 耿智敏, 仵正, 程亚丽. 意外胆囊癌病人预后列线图模型的构建[J]. 外科理论与实践, 2024, 29(01): 40-45. |
[6] | 张亦凡, 鲁逸权, 郝风节, 王俊青. 多倍体肝细胞的生理功能及其病理性改变的相关疾病[J]. 外科理论与实践, 2023, 28(06): 574-579. |
[7] | 王书奎, 顾心亮. tsRNA作为肿瘤诊断和预后标志物的研究进展[J]. 诊断学理论与实践, 2023, 22(05): 413-420. |
[8] | 葛焱, 王国鑫, 王佳卉, 安源, 赵冰, 盛慧球, 马丽. 双重滤过血浆置换对高脂血症性急性胰腺炎的疗效分析[J]. 外科理论与实践, 2023, 28(05): 448-453. |
[9] | 李岳峰, 洪进, 李志安, 阮国栋, 陈伟国. HER2阳性乳腺癌接受曲妥珠单抗辅助治疗病人预后分析(附1 246例报告)[J]. 外科理论与实践, 2023, 28(05): 469-476. |
[10] | 杨奕, 杨兴霞, 金思励, 张旭, 朱娟英, 陈小松. 术前MRI检查在乳腺导管原位癌保乳手术的临床应用研究[J]. 外科理论与实践, 2023, 28(04): 378-382. |
[11] | 白娅娅, 唐碧雯, 胡月亮, 左君丽, 姚玮艳. 71例嗜酸细胞性胃肠炎的临床特征和预后分析[J]. 内科理论与实践, 2023, 18(04): 270-277. |
[12] | 胡静静, 沈银忠, 刘莉, 卢洪洲. 艾滋病合并播散性非结核分枝杆菌病诊治现状及研究进展[J]. 诊断学理论与实践, 2023, 22(04): 402-406. |
[13] | 张兰兰, 杨巧, 聂尊珍, 郭英. 胸膜SMARCA4缺失未分化肿瘤1例报告[J]. 诊断学理论与实践, 2023, 22(04): 389-392. |
[14] | 刘英婷, 易红梅, 王雪, 杨春雪, 欧阳斌燊, 许海敏, 王朝夫. 十二指肠型滤泡性淋巴瘤17例临床病理特征及预后分析[J]. 诊断学理论与实践, 2023, 22(04): 362-368. |
[15] | 李一林, 陈杨, 李艳艳, 冯旭娇, 章程, 李健, 沈琳. 循环肿瘤细胞检测在常见恶性肿瘤精准医学中的应用和展望[J]. 诊断学理论与实践, 2023, 22(04): 332-340. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||